<DOC>
	<DOC>NCT00264901</DOC>
	<brief_summary>This trial is conducted in the United States of America (USA). This trial aims for a comparison of the safety and efficacy in subjects with type 2 diabetes using either self titration or physician guided titration according to the local standard of care.</brief_summary>
	<brief_title>Comparison of Self Adjustment Versus Standard of Care Treatment in Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Diagnosis of type 2 diabetes HbA1C &lt;= 12.0% within the past 12 months; BMI &lt;= 45.0 kg/m2 Initiation, addition of, change to, or continuation of basal insulin therapy with insulin detemir as deemed necessary by Investigator Anticipated change in concomitant medication known to interfere with glucose metabolism such as systemic steroids, nonselective betablockers or mono amine oxidase (MAO) inhibitors. Proliferative retinopathy or maculopathy that has required acute treatment within the last 6 months. Any glucose lowering medication that is not indicated in combination with insulin, such as GLP1 Analogues Known hypoglycemia unawareness or recurrent major hypoglycemia, as judged by the Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>